Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Spikevax

(mRNA-1273)

PreclinicalRNA therapy

This is a COVID-19 vaccine that teaches your body's immune system to recognize and fight the coronavirus that causes COVID-19, helping prevent serious illness and death from the disease.[1] Spikevax is currently being investigated across 1 indication[3], with its most advanced program in Preclinical.[1]

Spikevax is one of 9 biologic programs targeting Pericarditis. It is currently in Preclinical.

1

Indications

34

Total Trials

4

Active Trials

8

Competitors

Pipeline

Status by Indication[3][1]

Indication

PericarditisActive, not recruiting

PericarditisPreclinical

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Pericarditis

#DrugCompanyPhaseTrials

Colcrys

Jazz Pharmaceuticals

Bayer Aspirin

Epidiolex

Jazz Pharmaceuticals

Kineret

SSwedish Orphan Biovitrum

RPH-104

UUnknown Sponsor

Cardiolrx

CCardiol Therapeutics Inc.

KPL-387

KKiniksa Pharmaceuticals International, plc

VTX2735

ZZomagen Biosciences Ltd.

Spikevax

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

ApprovedRecruiting

SARS-Cov-2

NCT07863635

COVID-19

NCT04834869

Q2 2027

ApprovedActive, not recruiting

SARS-Cov-2

NCT07266558

Q3 2029

Phase 2Recruiting

SARS-Cov-2

NCT07808697

Clinical

Trials by Indication[1]

COVID-1920 trials

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04283461·120 enrolled

COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients

Completed·HH. Lee Moffitt Cancer Center and Research Institute··NCT05054218·336 enrolled

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT04785144·135 enrolled

Show 17 more trials

Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination

Withdrawn·MMaria Joyera Rodríguez·Phase 2·NCT04930770

A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants

Completed· Moderna logo

Moderna·Phase 2/3·NCT04927065·5,161 enrolled

COVID-19 Vaccines Safety Tracking (CoVaST)

Recruiting·MMasaryk University··NCT04834869·30,000 enrolled

A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19

Completed· Moderna logo

Moderna·Phase 3·NCT04470427·30,415 enrolled

A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19

Completed· Moderna logo

Moderna·Phase 2/3·NCT04649151·4,328 enrolled

A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters

Completed· Moderna logo

Moderna·Phase 2·NCT05137236·540 enrolled

A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years

Unknown status·SSinocelltech Ltd.·Phase 2·NCT05345873·300 enrolled

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT05289037·1,270 enrolled

Establishing Immunogenicity and Safety of Needle-free Intradermal Delivery of mRNA COVID-19 Vaccine

Unknown status·LLeiden University Medical Center·Phase 2·NCT05315362·20 enrolled

Adaptive Immune Response to COVID-19 Vaccination

Unknown status·UUniversity Medicine Greifswald··NCT04826770·70 enrolled

A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19

Completed· Moderna logo

Moderna·Phase 2/3·NCT05249829·3,548 enrolled

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

Completed· Moderna logo

Moderna·Phase 3·NCT04860297·234 enrolled

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Completed· Moderna logo

Moderna·Phase 1·NCT04813796·104 enrolled

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

Completed· Moderna logo

Moderna·Phase 2/3·NCT04796896·11,942 enrolled

Immunogenicity After COVID-19 Vaccines in Adapted Schedules

Completed·UUniversiteit Antwerpen·Phase 4·NCT06189040·580 enrolled

The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine

Unknown status·—·Phase 1/2·NCT05132855·340 enrolled

A Phase 4 Pragmatic, Randomized Trial to Evaluate the Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19

Completed·TTor Biering-Sørensen·Approved·NCT07279766·41,060 enrolled

SARS-CoV-24 trials

Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT04889209·867 enrolled

A Phase 3b/4, Open-label Study to Assess the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Recruiting· Moderna logo

Moderna·Approved·NCT07863635·600 enrolled

A Phase 2, Randomized, Observer-Blind, Dose Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age

Recruiting· Moderna logo

Moderna·Phase 2·NCT07808697·300 enrolled

Show 1 more trial

A Phase 4, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of mRNA-1283 And mRNA-1273 Variant-Containing Formulation in Adults 50 to 64 Years of Age Without Underlying Conditions That Put Them at High Risk for Severe Outcomes From COVID-19

Active, not recruiting· Moderna logo

Moderna·Approved·NCT07266558·30,000 enrolled

Influenza2 trials

A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old

Completed· Moderna logo

Moderna·Phase 1/2·NCT05375838·550 enrolled

A Study on the Immune Response and Safety of the Shingles Vaccine and the Influenza Vaccine When Either is Given to Healthy Adults at the Same Time or Following a COVID-19 Booster Vaccine

Completed· GSK logo

GSK·Phase 3·NCT05047770·2,013 enrolled

mRNA Vaccine1 trial

A Study of Modified mRNA Vaccines in Healthy Adults

Completed· Moderna logo

Moderna·Phase 1·NCT05397223·308 enrolled

Secondary Progressive Multiple Sclerosis1 trial

Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC)

Completed· Novartis logo

Novartis·Phase 4·NCT04792567·41 enrolled

6 more indications

Kidney Transplant1 trial

Homologous vs Heterologous Third Vaccination in Kidney Transplant Recipients Kidney Transplant Recipients

Unknown status·MMedical University of Vienna·Phase 2·NCT05324319·200 enrolled

Vaccination1 trial

RECOVAC Repeated Vaccination Study

Completed·UUniversity Medical Center Groningen·Phase 4·NCT05030974·336 enrolled

Pericarditis1 trial

A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine

Completed· Moderna logo

Moderna··NCT06113692·1,169 enrolled

Lung Transplant Recipient1 trial

High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients

Terminated·UUniversity of California, Los Angeles·Phase 1/2·NCT05280158·19 enrolled

Vaccine1 trial

Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

Unknown status·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04748471·180 enrolled

Immunogenicity1 trial

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT05158140·850 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for mRNA-1273. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mRNA-1273 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mRNA-1273. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: RNA therapy[2]
Highest Phase: Preclinical[1]
Company: Moderna

Related News